Dilitiazem in Comparison with metoprolol in stable angina pectoris
- 1 November 1988
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 9 (11) , 1194-1199
- https://doi.org/10.1093/oxfordjournals.eurheartj.a062429
Abstract
The efficacy of diltiazem in comparison with metoprolol in chornic stable angina was asessted in 33 male patients during a 15-week blind cross-over study. After an initial two-week run-in period, baseline measuremens were made. Subsequently,the patients enered a cross-over study consisting of two six-week treatment periods with diltiazem 240 mg (60 mg q.i.d.)or metoprol 200 mg (100 mg b.i.d.).Dose adjustment to either 360 mg diltiazem(120t.i.d.)or 400 mg metoprolol(200b.i.d.)was allowed two weeks after the start of treatment. There was a one-week washout period between the two treatment periods. Compared to baseline values both drugs reduced the number of anginal attacks (diltiazem −55%,p=0.02; metoprolol −73%,P=0.01)and showed improvement of the measured exercise variables(exercise duration; diltiazem +16%,P<0.001;meoprolol +4%,P=NS; time to angina:diltiazem +21%,P=0.02,metoprolol + 14%, P =NS;maximal ST-depression: diltiazem +13%,P =NS,metoprolol +33%,P=0.002).No significant change in LVEF was noticed.Both drugs reduced the mean heart rate on Holter tape (diltiazem−11%,P=0.006;metoprolol −14%, P=0.004). No effects on conduction were noticed. Although at the borderline of significance, diltiazem increased the total exercise duration as compared to metoprolol (16 vs, 4%,P=0.05). It is concluded that diltiazem improves exercise tolerance in patients with stable angina pectoris and appears to be a safe and effective alternative to the beta-blocking agent metoprolol.Our findings underscore the value of diltiazem as a monotherapeutic drug for the treatment of stable angina.Keywords
This publication has 0 references indexed in Scilit: